论文部分内容阅读
目的:观察依地福新对人宫颈癌Hela细胞的体外生长抑制作用,并进一步探讨其作用机制。方法:细胞中分别加入不同浓度的依地福新(0.5、1.0、5.0、10.0μmol.L-1)处理96h,并设立未加依地福新的对照组。应用MTT法检测细胞增殖活性;流式细胞仪检测细胞周期分布;染色法检测细胞凋亡率。结果:与对照组比较,不同浓度依地福新处理Hela细胞24～96h后,细胞增殖显著受到抑制,并呈浓度及时间依赖性;1.0、5.0、10.0μmol.L-1浓度依地福新处理72h后,Hela细胞G0/G1期细胞数量显著增加,S期细胞数量显著降低(P<0.01);各浓度组细胞凋亡率均显著增加(P<0.01)。结论:依地福新对Hela细胞具有生长抑制作用,其机制可能与阻滞细胞周期及诱导凋亡有关。
OBJECTIVE: To observe the inhibition of efavirenz on human cervical carcinoma Hela cells in vitro and to explore its mechanism. Methods: The cells were treated with different concentrations of efavirenz (0.5,1.0,5.0,10.0μmol.L-1) for 96h, and the control group without etanercept was established. Cell proliferation activity was detected by MTT assay. Cell cycle distribution was analyzed by flow cytometry. Apoptosis rate was detected by staining. Results: Compared with the control group, the proliferation of Hela cells treated with different concentrations of efavil was significantly inhibited in 24-96 h in a dose- and time-dependent manner. The concentrations of 1.0, 5.0, and 10.0 μmol·L-1 of efavirenz After 72h treatment, the number of cells in G0 / G1 phase increased significantly and the number of S phase cells decreased significantly (P <0.01). The apoptosis rate of Hela cells increased significantly (P <0.01). CONCLUSION: EIFF can inhibit the growth of Hela cells. The mechanism may be related to arresting cell cycle and inducing apoptosis.